CLAIRE WONG BLACK 9645
MICHAEL JOHNSON 12235
DENTONS US LLP
1001 Bishop Street, Suite 1800
Honolulu, Hawai‘i 96813
Telephone: (808) 524-1800
Facsimile: (808) 524-4591
E-Mail: claire.black@dentons.com
michael.johnson@dentons.com

Counsel for Plaintiffs
ABBVIE INC., ALLERGAN, INC.,
DURATA THERAPEUTICS, INC.,
ABBVIE PRODUCTS LLC,
PHARMACYCLICS LLC, AND
ALLERGAN SALES, LLC
Additional counsel listed on next page

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF HAWAII

ABBVIE INC. (a Delaware corporation); ALLERGAN, INC. (a Delaware corporation); DURATA THERAPEUTICS, INC. (a Delaware corporation); ABBVIE PRODUCTS LLC (a Georgia limited liability company); PHARMACYCLICS LLC (a Delaware limited liability company); ALLERGAN SALES, LLC (a Delaware limited liability company),

Plaintiffs,

v.

ANNE E. LOPEZ, in her official capacity as ATTORNEY GENERAL OF THE STATE OF HAWAI‘I,

Defendant.

Civil No. 1:25-cv-00230-SASP-WRP (Civil)

PLAINTIFFS’ STATUS REPORT REGARDING TRIAL EXHIBITS AND EVIDENCE DESIGNATED CONFIDENTIAL BY THIRD PARTIES

Trial Date: November 16, 2026

Judge: Hon. Shanlyn A.S. Park

MEREDITH M. POHL, *pro hac vice*
KING & SPALDING LLP
1700 Pennsylvania Avenue, N.W.
Suite 900
Washington, D.C. 20006
Telephone: (202) 626-9553
E-mail: mpohl@kslaw.com

PHILIP R. GREEN 11632
KING & SPALDING LLP
1180 Peachtree Street, N.E.
Atlanta, Georgia 30309
Telephone: (404) 572-4600
E-Mail: pgreen@kslaw.com

MATTHEW S. OWEN, *pro hac vice*
NICHOLAS A. BELL, *pro hac vice*
GIBSON, DUNN & CRUTCHER
1700 M St., N.W.
Washington, D.C. 20036
Telephone: (202) 955-8500
E-mail: mowen@gibsondunn.com
nbell@gibsondunn.com

MEGAN HULCE, *pro hac vice*
GIBSON, DUNN & CRUTCHER
2001 Ross Ave., Suite 2100
Dallas, TX 75201
Telephone: (214) 571-2901
E-mail: mhulce@gibsondunn.com

Counsel for Plaintiffs ABBVIE INC., ALLERGAN, INC., DURATA THERAPEUTICS, INC., ABBVIE PRODUCTS LLC, PHARMACYCLICS LLC, AND ALLERGAN SALES, LLC

STATUS REPORT

Pursuant to this Court's November 2, 2026 Order, Plaintiffs (collectively, "AbbVie") respectfully write to provide the Court with a status report as to any remaining, outstanding sealing disputes ahead of the trial scheduled to begin on November 16, 2026. As a brief summary, at the time of this filing, only ***four*** third-party movants' disputes remain before the Court, and AbbVie has narrowed the scope of those disputes to ***six*** total documents (five exhibits and one sub-exhibit).[1]

Exhibit	Document	Movant(s)	Allegedly Sensitive Information
PX 18	Contract between Queen's Medical Center and Walgreen Co.	Walgreens	Undisclosed
PX 47, **PX 47-A** (sub-exhibit)	Contract, and amendment, between Walgreen Co. and Castle Medical Center	Walgreens	Undisclosed
PX 75	Declaration of Andrew Bowling	Accredo	Fees
PX 78	Declaration of Darren West	Wellpartner	Revenue figure
PX 79	Declaration of Christian Reid	CVS Longs	Revenue figure

As explained in greater detail below, AbbVie has reached agreement resolving two of the third-party movants' disputes and believes it is close to agreement with another two third parties pending their respective clients' final sign-off. AbbVie has no disputes with the Attorney General related to any pretrial disclosures, exhibits for

[1] AbbVie will lodge hard copies of these documents with the Court, in the event the parties moving to seal have not already done so.

trial, or as a result of the follow-up meet-and-confer process regarding the sealing motions filed by third parties.

After productive follow-up meet-and-confers with the third parties who moved to seal last week on October 28, 2026, AbbVie and the third parties have been able to significantly narrow the scope of the disputes pending before the Court:

- There is no remaining dispute between AbbVie and Verity Solutions Group, Inc. (Dkt. 187), and Hawai‘i Pacific Health ("HPH").[2] Those third parties will either withdraw their previous motions to seal, or those motions may be appropriately denied as moot, as instructed by the Court.
- In addition, AbbVie is close to agreement with two third-party movants that would moot their previous motions to seal.[3]
    - As to Optum Pharmacy 702 LLC ("Optum"), AbbVie and Optum are confident they will reach a resolution to Optum's motion (Dkt.

[2] Although HPH did not file a motion to seal pursuant to the pretrial schedule, *see* Dkt. 148, and was therefore not covered by the Court's November 2 Order, AbbVie nevertheless met and conferred with HPH to ensure that there are no disputes regarding the use of HPH-produced information at trial. Following those discussions, counsel for both AbbVie and HPH have confirmed there are none.

[3] Despite all participants' diligent efforts, due to the various time differences of third parties' client representatives, it was not possible to receive final confirmation prior to this filing on Wednesday, November 4, 2026.

190) before the Friday, November 6 status conference.[4]

- Similarly, with respect to Queen's Health Systems and the Queen's Medical Center's (Queen's) motion (Dkt. 188), AbbVie and Queen's believe they will reach a resolution to Queen's previous motion to seal before the Friday, November 6 status conference.[5]

AbbVie intends to promptly file a supplemental status report tomorrow, November 5, 2026, providing the Court with the status of the Optum and Queen's disputes ahead of Friday's status conference, including whether the parties have reached full agreement such that no dispute remains for the Court to resolve or, if a dispute remains, the specific contours of that dispute.[6]

---

[4] AbbVie received written confirmation of Optum's counsel's agreement to this representation via email at 9:29pm EST. In the event that AbbVie cannot resolve its dispute with Optum, the only remaining documents in dispute are PX40 and sub-exhibit 40-D. The parties have discussed potential limited redactions to pricing terms and will provide those details to the court should they become necessary.

[5] AbbVie received written confirmation of Queen's counsel's agreement to this representation at 3:12am EST. In the event that AbbVie cannot resolve its dispute with Queen's, AbbVie narrowed the scope of its intended Queen's-produced exhibits to 7 documents: PX15-19, PX21, and sub-exhibit PX21-B. It is AbbVie's position that any dispute over these seven documents could be resolved through narrow redactions, if necessary, and would not require wholesale sealing.

[6] The Public First Law Center has filed its position with respect to the pending third parties' motions to seal filed on October 28, 2026. Dkt. 216. AbbVie believes that many of the disputes have been substantially narrowed since those filings, and regardless, the Public First Law Center's view is already represented because AbbVie has explained why sealing the courtroom is unwarranted.

As previewed above, despite the additional meet-and-confer process, AbbVie and third parties Accredo Health Group, Inc. ("Accredo"), Walgreen Co. ("Walgreens"), Longs Drug Stores California LLC ("CVS Longs"), and Wellpartner, LLC ("Wellpartner") could not reach full resolution of their disputes. However, AbbVie has narrowed the disputes to six total documents. *See* Chart at p. 1.

Pending Questions. As to those six documents, there are two common questions for the Court:

1. Do the six documents reveal information that constitutes sensitive information warranting sealing a public courtroom, or redacting transcripts or exhibits?

2. If so, what procedures should the Court put in place to balance the public's right of access against the need to protect third parties' confidential information?

If the Court answers "no" to the first question and decides none of the information at issue is a trade secret warranting sealing, that ends the inquiry.

As to the first question, Accredo, Walgreens, CVS Longs, and Wellpartner must satisfy the "rigorous" compelling-reasons standard. *See Bloom v. Zuffa*, 2026 WL 2031777, at *2 (D. Nev. July 13, 2026). As articulated more fully in AbbVie's proposed response to the various motions to seal, *see* Dkt. 202-2, AbbVie continues to disagree that these six exhibits contain trade secret or other information warranting sealing, redaction, or closure of the courtroom. During the telephonic meet-and-confers on November 4, 2026, all of the third parties discussed below

indicated they stand on the positions articulated in their October 28 motions to seal.

Walgreens. As reflected in the above chart, Walgreens seeks to seal two contracts between Walgreens and Hawai'i 340B hospitals (called "covered entities"). During the additional meet-and-confers on November 4, 2026, Walgreens indicated it would only agree to withdraw its request to limit access to the courtroom to individuals who fall within the existing protective order's "Attorneys' Eyes Only" limitation if AbbVie would agree to "significant" redactions to the two contracts used in the courtroom. Given that Walgreens filed its motion to seal a week ago, Dkt. 186, and must therefore have had an understanding of the information it believed to be commercially sensitive when it filed, AbbVie inquired as to the specific provisions Walgreens believed warranted sealing. ***Walgreens was unable to identify exactly what provisions of the contracts it would seek to redact*** as commercially sensitive information ahead of this filing. That poses an issue for AbbVie where, for example, certain provisions merely describe facts like the nature of the relationship between the parties and who holds title to drugs purchased pursuant to the agreement. Those kinds of provisions are neither trade secrets nor commercially sensitive,[7] but Walgreens could not confirm that it would not include such provisions within its requested redactions. Setting aside Walgreens' request

[7] Those provisions do not contain, for example, "a formula, pattern, compilation, program, device, method, technique, or process" that has "independent economic value." HRS § 482B-2 (defining "trade secret"); 18 U.S.C. § 1839(3) (similar).

for redactions, AbbVie continues to oppose any request to seal the courtroom and offered Walgreens several mitigating options (including more limited redactions to pricing terms). As part of the meet-and-confer process, AbbVie also pointed Walgreens' counsel to publicly available information about its contract pharmacy fees published in various government documents.[8] There is also at least one fully unredacted Walgreens 340B contract publicly available online.[9] This dispute is fully briefed and ripe for the Court's resolution.

Accredo. Following additional meet-and-confers on November 4, 2026, the single exhibit still at issue with respect to Accredo is the declaration submitted by Accredo's Senior Director of Product Management, Andrew Bowling ("Accredo Declaration"). The Accredo Declaration contains one paragraph discussing the range of 340B dispensing fees Accredo charges covered entities in Hawai‘i. Accredo maintains that disclosure of the general 340B dispensing fee range for Hawai‘i covered entities (not the 340B fees charged to any particular covered entity)

[8] U.S. Gov't Accountability Off., GAO-18-480, *Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement*, 25-30, 51-54 app. I (2018), https://tinyurl.com/5pjketkb; Majority Staff of S. Comm. on Health, Educ., Lab., & Pensions, 119th Cong., Congress Must Act to Bring Needed Reforms to the 340B Drug Pricing Program 18-24 (2025) ("Senate HELP Report"), https://tinyurl.com/mpnutdth (listing CVS, Wellpartner, and Walgreens dispensing fees and TPA fees under contracts with multiple covered entities).

[9] 340B Contract Pharmacy Services Agreement Between Monterey County Department of Health and Walgreen Co., https://tinyurl.com/murnz433.

is commercially sensitive information. AbbVie explained to Accredo that it disagrees that the range constitutes commercially sensitive information, as it does not identify the fees associated with any one covered entity over another but rather the spectrum of fees Accredo charges in Hawai‘i—an issue relevant to AbbVie's takings claim. This dispute is fully briefed and ripe for the Court's resolution.

CVS Longs and Wellpartner. The remaining two exhibits are declarations from employees at CVS Longs and Wellpartner ("CVS Longs Declaration" and "Wellpartner Declaration," respectively). The CVS Longs and Wellpartner Declarations each contain a paragraph stating the amount of revenue that CVS Longs and Wellpartner, respectively, made from 340B drug sales in Hawai‘i between May 2025 and May 2026. Both CVS Longs and Wellpartner contend that the amount of their 340B Program revenue is commercially sensitive information. AbbVie explained to CVS Longs and Wellpartner's counsel that it opposes this request to redact revenue information because the amount of revenue generated is neither commercially sensitive nor a trade secret. Because CVS Health—the parent company of both CVS Longs and Wellpartner—is publicly traded, it regularly discloses its revenue as part of required annual filings. And Wellpartner, in particular, has disclosed its annual revenue from 340B TPA fees in publicly available

government documents.[10] This dispute is fully briefed and ripe for the Court's resolution.

If the Court disagrees or believes that some or all of the documents at issue contain trade secrets, the Court must answer the second question posed above and determine what trial or post-trial procedures should be put in place. In the event the Court reaches the second question regarding potential sealing procedures, AbbVie met and conferred with the third-party movants on potential paths forward to aid in the Court's decision:

- During the November 4, 2026 meet-and-confer process, two third parties (Accredo and Walgreens) indicated they would agree to in-camera review of the redacted material by the Court, if the material was neither publicly displayed in the courtroom nor elicited orally during questioning or testimony of the witness.
- Further, other third parties, like Castle Medical Center, have indicated they have no objection to materials that come into evidence being used during witness examination in open court without limitation but have requested that they be permitted post-trial to petition for redaction of

[10] *See* Senate HELP Report, *supra* n.5, at 106 (Response by Wellpartner to Senate inquiry explaining Wellpartner made between $147 million and $382 million in 340B fees between 2019 and 2023).

exhibits or trial transcripts describing confidential, sensitive information before they are posted to the public docket. AbbVie has previously indicated to the third parties that it does not oppose this request.[11]

AbbVie's position is that none of this information should be sealed and the courtroom should remain open. In the alternative, if the Court concludes that some sealing is warranted, then (1) redactions to trial exhibits should be narrowly tailored to, at most, specific pricing amounts, and (2) the Court may instruct witnesses not to quote the exact terms redacted so that the courtroom may remain open when redacted trial exhibits are used.

* * *

Finally, in accordance with the Court's November 2, 2026 Order, AbbVie has attached to this status report a list of all exhibits that AbbVie may tender during trial, with specific notation of which exhibits have been identified by any third party as material deemed Confidential or Attorneys' Eyes Only ("AEO") under the protective order. The list reflects substantial narrowing, as evidenced by the nonconsecutive nature of Plaintiffs' exhibit numbering. In all, AbbVie withdrew 105 documents

[11] It is AbbVie's understanding that Castle Medical Center ultimately decided not to move to seal on the October 28 deadline because it intends to seek selective post-trial redactions of any Castle-produced documents used at trial before those documents are posted to the public docket.

from its original proposal. AbbVie will promptly provide the Court with a further revised version of the exhibit list should resolution of the Optum or Queen's dispute require additional amendment.

DATED: Honolulu, Hawai'i, November 4, 2026.

/s/ Claire Wong Black
CLAIRE WONG BLACK
MICHAEL JOHNSON
MATTHEW S. OWEN, *pro hac vice*
MEREDITH M. POHL, *pro hac vice*
MEGAN HULCE, *pro hac vice*
NICHOLAS A. BELL, *pro hac vice*
PHILIP R. GREEN

Counsel for Plaintiffs
ABBVIE INC., ALLERGAN, INC.,
DURATA THERAPEUTICS, INC.,
ABBVIE PRODUCTS LLC,
PHARMACYCLICS LLC, AND
ALLERGAN SALES, LLC

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 1	Pharmaceutical Pricing Agreement	Scheidler	
PX 2	340B: Integrity Initiative: September 1, 2026 Update	Scheidler	
PX 3	Hawaii Contract Pharmacy Discount Volume Graphs (FRE 1006)	Scheidler	
PX 4	Hawaii Financial Impact Graph (FRE 1006)	Scheidler	
PX 5	Nationwide Financial Impact Graph (FRE 1006)	Scheidler	
PX 6	Declaration of Edward Scheidler in *AbbVie Inc. v. Lopez*	Scheidler	
PX 7	340B Integrity Initiatvie: March 29, 2023 Announcement	Scheidler	
PX 8	340B Integrity Initiative: April 30, 2024 Update	Scheidler	
PX 12	Declaration of Eric King in *AbbVie Inc. v. Lopez*	King	
PX 13	Declaration of Eric King in *PhRMA v. Lopez*	King	
PX 14	OPAIS, Queen's Medical Center	King	
PX 15	Queen's Health Systems, 340B Program Policy	King	Confidential (Pending resolution)
PX 16	Queen's Health System, 340B Program Policy	King	Confidential (Pending resolution)
PX 17	Queen's Health Systems, 340B Policy & Procedure Manual	King	Confidential (Pending resolution)
PX 18	340B Contract Pharmacy Services Agreement 594931 between Queen's Medical Center and Walgreen Co. (10/01/2018)	King	AEO **Walgreens**: No visual display and AEO personnel only **Queen's**: Pending resolution
PX 19	Pharmacy Services Agreement between Queen's Medical Center and CVS Pharmacy, Inc. (10/12/2018)	King	Confidential (Pending resolution)
PX 21	Contract Pharmacy Services Agreement 500180 between Queen's Medical Center and Queen's Development Corporation (03/01/2018)	King	Confidential (Pending resolution)
PX 21-B	Second Amendment to Contract Pharmacy Services Agreement 500180 between Queen's Medical Center and Queen's Development Corporation (11/1/2021)	King	Confidential (Pending resolution)
PX 24	Declaration of Jennifer Dacumos in *AbbVie Inc. v. Lopez*	Dacumos	
PX 25	Declaration of Jennifer Dacumos in *AstraZeneca v. Lopez*	Dacumos	
PX 26	Declaration of Jennifer Dacumos in *PhRMA v. Lopez*	Dacumos	
PX 27	OPAIS, Pali Momi Medical Center (Terminated)	Dacumos	
PX 28	OPAIS, Pali Momi Medical Center	Dacumos	
PX 29	OPAIS, Straub Clinic & Hospital (Terminated)	Dacumos	
PX 30	OPAIS, Straub Clinic & Hospital	Dacumos	
PX 31	FY 23-25 340b Program Savings	Dacumos	
PX 32	Michael Robinson testimony in support of HB 712 on behalf of Hawaii Pacific Health (03/19/2025)	Dacumos	
PX 33	Pali Momi Medical Center 340B Program Operations Policy & Procedure	Dacumos	Confidential (No dispute)
PX 34	Straub Medical Center 340B Program Operations Policy & Procedure	Dacumos	Confidential (No dispute)
PX 35	Pharmacy Services Agreement bewtween Straub Clinic & Hospital dba Straub Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (10/12/2020)	Dacumos	Confidential (No dispute)

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 35-G	Seventh Amendment to Pharmacy Services Agreement bewtween Straub Clinic & Hospital dba Straub Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (09/18/2024)	Dacumos	Confidential (No dispute)
PX 35-H	Eighth Amendment to Pharmacy Services Agreement bewtween Straub Clinic & Hospital dba Straub Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (10/29/2024)	Dacumos	Confidential (No dispute)
PX 36	Pharmacy Services Agreement between Pali Momi Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (10/13/2020)	Dacumos	Confidential (No dispute)
PX 36-D	Third Amendment to Pharmacy Services Agreement between Pali Momi Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (09/18/2024)	Dacumos	Confidential (No dispute)
PX 36-E	Fourth Amendment to Pharmacy Services Agreement between Pali Momi Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C. (06/25/2025)	Dacumos	Confidential (No dispute)
PX 38	340B Contract Pharmacy Service Agreement between Pali Momi Medical Center and Accredo Health Group	Dacumos	Confidential (No dispute)
PX 39	340B Contract Pharmacy Service Agreement between Straub Clinic & Hospital and Accredo Health Group Inc. (10/1/2020)	Dacumos	Confidential (No dispute)
PX 39-C	Amendment to 340B Contract Pharmacy Service Agreement between Straub Clinic & Hospital and Accredo Health Group Inc. (01/01/2024)	Dacumos	Confidential (No dispute)
PX 39-D	Amendment to 340B Contract Pharmacy Service Agreement between Straub Clinic & Hospital and Accredo Health Group Inc. (01/22/2025)	Dacumos	Confidential (No dispute)
PX 40	340B Pharmacy Services Agreement between Straub Clinic & Hospital and Optum Pharmacy 702, LLC (10/01/2020)	Dacumos	Confidential (Pending resolution)
PX 40-D	Fourth Amendment to 340B Pharmacy Services Agreement between Straub Clinic & Hospital and Optum Pharmacy 702, LLC (01/04/2023)	Dacumos	Confidential (Pending resolution)
PX 43	OPAIS, Castle Medical Center dba Adventist Health Castle	Stipulated / Jacobsen (Dep. Deg.)	
PX 44	Adventist Health Castle, Policy & Procedure: 340B Contract Pharmacy Prescription Management	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 45	Adventist Health System/West, Consolidated Financial Statements and Supplementary Information Years Ended December 31, 2025 and 2024	Stipulated / Jacobsen (Dep. Deg.)	
PX 46	Castle Medical Center 2025 Contract Pharmacy Revenues	Stipulated / Jacobsen (Dep. Deg.)	
PX 47	340B Contract Pharmacy Services Agreement between Adventist Health System/West DBA Adventist Health and Walgreen Co.	Stipulated / Jacobsen (Dep. Deg.)	AEO **Walgreens**: No visual display and AEO personnel only

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 47-A	Covered Entity Agreement between Walgreen Co. and Castle Medical Center	Stipulated / Jacobsen (Dep. Deg.)	AEO **Walgreens**: No visual display and AEO personnel only
PX 48	Pharmacy Services Agreement between Castle Medical Center and CVS Pharmacy, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 48-A	First Amendment to Pharmacy Services Agreement between Castle Medical Center and CVS Pharmacy, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 48-B	Second Amendment to Pharmacy Services Agreement between Castle Medical Center and CVS Pharmacy, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 48-C	Third Amendment to Pharmacy Services Agreement between Castle Medical Center and CVS Pharmacy, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 49	Wellpartner Services Agreement between Adventist Health System/West and Wellpartner, LLC	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 50	340B Contract Pharmacy Services Agreement between Castle Medical Center and Accredo Health Group, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 50-A	First Amendment to 340B Contract Pharmacy Services Agreement between Castle Medical Center and Accredo Health Group, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 50-B	Pharmacy Location Notice Regarding 340B Contract Pharmacy Services Agreement between Castle Medical Center and Accredo Health Group, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 51	340B Pharmacy Services Agreement between Sam's Club and Castle Medical Center dba Adventist Health Castle	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 52	340B Retail Pharmacy Program Management Agreement between Envision Pharmaceutical Services, Inc. and Adventist Health	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 52-A	Assignment, Assumption, and Amendment of 340B Retail Pharmacy Program Management Agreement between Envision Pharmaceutical Services, Inc. and Adventist Health	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 53	340B Management Services Agreement between Adventist Health System/West d/b/a Adventist Health and RxStrategies, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 53-A	Amendment #1 to 340B Management Services Agreement between Adventist Health System/West d/b/a Adventist Health and RxStrategies, Inc.	Stipulated / Jacobsen (Dep. Deg.)	AEO (No dispute)
PX 68	Hilo Benioff Medical Center 340B Program policy document	Stipulated / Shiroma (Dep. Deg.)	Confidential (No dispute)
PX 69	Ka'u Hospital 340B Program policy document	Stipulated / Shiroma (Dep. Deg.)	Confidential (No dispute)
PX 70	340B Contract Pharmacy Services Agreement between Hilo Medical Center and Walgreen Co.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 70-A	Amendment No. 1 to 340B Contract Pharmacy Services Agreement between Hilo Medical Center and Walgreen Co.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 71	340B Contract Pharmacy Services Agreement between Hilo Medical Center and East Hawaii Health Pharmacy	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 72	Pharmacy Services Agreement between Hilo Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 72-A	First Amendment to Pharmacy Services Agreement between Hilo Medical Center and CVS Pharmacy, Inc. and Caremark, L.L.C.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 73	340B Contract Pharmacy Services Agreement between Kau Hospital and East Hawaii Health Pharmacy	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 74	Pharmacy Services Agreement between Hawaii Health Systems Corp., East Hawii Region, its Ka'u Hospital and CVS Pharmacy Inc. and Caremark, L.L.C.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 74-A	First Amendment to Pharmacy Services Agreement between Hawaii Health Systems Corp., East Hawii Region, its Ka'u Hospital and CVS Pharmacy Inc. and Caremark, L.L.C.	Stipulated / Shiroma (Dep. Deg.)	AEO (No dispute)
PX 75	Declaration of Andrew Bowling in *AbbVie Inc. v. Lopez*	Stipulated / Bowling (Declaration)	AEO **Accredo:** Redactions or *in camera* use only.
PX 76	340B Contract Pharmacy Services Agreement between Ho'ola Lahui Hawaii and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 76-A	Amendment 1 to 340B Contract Pharmacy Services Agreement between Ho'ola Lahui Hawaii and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 77	340B Contract Pharmacy Services Agreement between Kapi'olani Medical Center for Women and Children and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 77-A	Amendment to 340B Contract Pharmacy Services Agreement between Kapi'olani Medical Center for Women & Children and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 77-C	Amendment to 340B Contract Pharmacy Services Agreement between Kapi'olani Medical Center for Women & Children and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 77-D	Amendment to 340B Contract Pharmacy Services Agreement between Kapi'olani Medical Center for Women & Children and Accredo Health Group, Inc.	Stipulated / Bowling (Declaration)	AEO (No dispute)
PX 78	Declaration of Darren West in *AbbVie Inc. v. Lopez*	Stipulated	AEO **Wellpartner**: Redactions or AEO personnel only
PX 79	Declaration of Christian Reid in *AbbVie Inc. v. Lopez*	Stipulated	AEO **CVS Longs**: Redactions or AEO personnel only
PX 80	42 U.S.C. 256b	Stipulated / Judicial Notice	

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 81	42 C.F.R. 10.20 et seq	Stipulated / Judicial Notice	
PX 82	HRSA, *Notice Regarding the 340B Rebate Model Pilot Program* , 91 Fed. Reg. 48,883 (Aug. 3, 2026)	Stipulated / Judicial Notice	
PX 83	HRSA, *340B Drug Pricing Program; Administrative Dispute Resolution Regulation* , 89 Fed. Reg. 28,643 (April 19, 2024)	Stipulated / Judicial Notice	
PX 84	HRSA, *Notice Regarding 340B Drug Pricing Program-Contract Pharmacy Services* , 75 Fed. Reg. 10,272 (March 5, 2010)	Stipulated / Judicial Notice	
PX 85	HRSA, *Notice Regarding Section 602 of the Veterans Health Care Act of 1992; Contract Pharmacy Services* , 61 Fed. Reg. 43,549 (Aug. 23, 1996)	Stipulated / Judicial Notice	
PX 86	HRSA, *Manufacturer Audit Guidelines and Dispute Resolution Process* , 61 Fed. Reg. 65,406 (Dec. 12, 1996)	Stipulated / Judicial Notice	
PX 89	James C. Robinson, Christopher Whaley & Sanket S. Dhruva, Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance, 390 NEW ENG. J. MED. 4 (2024)	Chen	
PX 90	Sunita Desai & J. Michael McWilliams, Consequences of the 340B Drug Pricing Program, 378 NEW ENG. J. MED. 6 (2018)	Chen Chandra	
PX 91	Rena M. Conti & Peter B. Bach, The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities (2014)	Chen	
PX 92	Sunita M. Desai & J. Michael McWilliams, 340B Drug Pricing Program and Hospital Provision of Uncompensated Care, 27 AM. J. MANAGED CARE 10 (2021)	Chen	
PX 93	Blue Cross Blue Shield of Vermont, Blue Cross VT 340B Testimony	Chen	
PX 94	Senate Committee on Health Education Labor & Pensions' April 2025 Majority Staff Report, Congress Must Act to Bring Needed Reforms to the 340B Drug Pricing Program	Stipulated / Judicial Notice / King / Dacumos	
PX 95	Department of Health and Human Services Office of Inspector General's February 4, 2014 Memorandum Report: Contract Pharmacy Arrangements in the 340B Program, OEI-05-13-00431	Stipulated / Judicial Notice	
PX 96	United States Government Accountability Office's June 2018 Report to Congressional Requester entitled Drug Discount Program – Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement	Stipulated / Judicial Notice	
PX 121	Knox et al. (2023) - Outcomes of the 340B Drug Pricing Program	Chen	
PX 122	Liu, Benjamin Y., et al., "Expansion of 340B Disproportionate Share Hospitals in the United States From 2010 to 2022," Health Services Research, March 14, 2025	Chen	

Exhibit No.	Document Title/Description	Sponsoring Witness	Designation / Movant Request
PX 123	Chang, Jessica, et al., "Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs," JAMA Health Forum, Vol. 4, No. 6, 2023, pp. 1-10	Chen	
PX 124	Bond, Amelia M., et al., "The Role of Financial Incentives in Biosimilar Uptake in Medicare: Evidence from the 340B Program," Health Affairs, Vol. 42, No. 5, 2023, pp. 632-641	Chen	
PX 125	Fein, Adam J., "EXCLUSIVE: For 2023, Five For-Profit Retailers and PBMs Dominate an Evolving 340B Contract Pharmacy Market," Drug Channel, July 11, 2023	Chen	
PX 127	IQVIA, Rory Martin & Kepler Illich, White Paper: Are discounts in the 340B Drug Discount Program Being Shared With Patients at Contract Pharmacies?	Alex Williams	
PX 131	Comment letter submitted by 340B Health in response to HRSA's proposed changes to the 340B Drug Pricing Program in 2023	Judicial Notice / Alex Williams	
PX 137	North Carolina State Treasurer, Overcharged: State Employees, Cancer Drugs, and the 340B Drug Pricing Program (May 8, 2024)	Stipulated / Judicial Notice / Alex Williams	
PX 139	Community Oncology Alliance, The 340B Drug Discount Program in Review: How Abuse of the 340B Program Is Hurting Patients (2017)	Alex Williams	
PX 143	United States Government Accountability Office's September 2011 Drug Pricing – Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement	Stipulated / Judicial Notice	
PX 144	Declaration of Krista M. Pedley, Director, Office of Pharmacy Affairs, Health Resources and Services Administration, United States Department of Health and Human Services, dated June 16, 2021	Stipulated/ Judicial Notice	
PX 146	HRSA, *ADR Decision Summaries*	Stipulated / Judicial Notice	
PX 148	Congressional Budget Office, *Growth in the 340B Drug Pricing Program* , September 2025	Stipulated / Judicial Notice / Alex Williams	
PX 149	HHS Assistant Secretary for Planning and Evaluation, *Mission v. Margin: Misaligned Incentives in the 340B Drug Pricing Program* (Oct. 8, 2026)	Stipulated / Judicial Notice / Alex Williams	
PX 153	*Univ. of Mich. Hosps. & Health Ctrs. et al.* , Operative Compl., 2:26-cv-11618 (E.D. Mich.)	Judicial Notice	
PX 155	HRSA ADR Decision in ADR ID: 230925-17	Stipulated / Judicial Notice	
PX 158	*Univ. of Mich. Hosps. & Health Ctrs. et al.* , CVS's Motion to Dismiss, 2:26-cv-11618 (E.D. Mich.)	Judicial Notice	
PX 158-A	*Univ. of Mich. Hosps. & Health Ctrs. et al.* , Brief in Support of CVS's Motion to Dismiss, 2:26-cv-11618 (E.D. Mich.)	Judicial Notice	